RxDoctor Payments Data

Michael Skolnick

Psychiatric/Mental Health · West Hartford, CTNPI 1144843616

Payments from drug & device makers

$1,633in general payments, 2019–2025

Across 77 payments — averaging $21.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$303
  • AbbVie$201
  • Teva Pharmaceuticals USA, Inc.$182
  • Neurocrine Biosciences, Inc.$167
  • Alkermes, Inc.$150
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$116
  • plus $514 from 11 others

What the payments were for

  • Food & beverage$1,55295%
  • Education$815%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,633 in reported general payments places this provider in the 80th percentile of 679 psychiatric/mental health providers in Connecticut.

See all psychiatric/mental health providers in Connecticut

Medicare billing

Part B allowed, 2024
$14,782
Medicare patients
33
Services billed
167

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VraylarCariprazine Hcl18$38,816
CaplytaLumateperone Tosylate13$21,557
Lurasidone Hcl48$6,534
TrintellixVortioxetine Hydrobromide14$6,527
Aripiprazole38$5,630
Hydroxyzine Hcl88$3,649
Venlafaxine Hcl ErVenlafaxine Hcl90$2,967
Bupropion XlBupropion Hcl71$2,861
Desvenlafaxine Succinate ErDesvenlafaxine Succinate39$2,548
Quetiapine Fumarate82$2,158
Duloxetine Hcl63$2,034
Olanzapine62$1,948
Fluoxetine Hcl53$1,742
Clonazepam211$1,653
Trazodone Hcl169$1,276

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar$201$38,81618 claims
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$116$21,55713 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$57$6,52714 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 679 psychiatric/mental health providers in Connecticut.

Other psychiatric/mental health in West Hartford

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →